Arkolith/Insider Trading/KIN/Form 4

Bevers Denise

DirectorKindred Biosciences, Inc. (KIN) · full profile →Form 4 · filed Aug 30, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
1 non-derivative · 12 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)146K$9.25$1.3M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)100K$0.50$50K0
Aug 27, 2021Disposed to issuer(D)75K—$00
Aug 27, 2021Disposed to issuer(D)150K—$00
Aug 27, 2021Disposed to issuer(D)80K—$00
Aug 27, 2021Disposed to issuer(D)46K$4.81$221K0
Aug 27, 2021Disposed to issuer(D)59K$5.80$342K0
Aug 27, 2021Disposed to issuer(D)100K$2.85$285K0
Aug 27, 2021Disposed to issuer(D)30K$5.65$170K0
Aug 27, 2021Disposed to issuer(D)59K$2.29$135K0
Aug 27, 2021Disposed to issuer(D)20K$8.35$170K0
Aug 27, 2021Disposed to issuer(D)96K$7.88$757K0
Aug 27, 2021Disposed to issuer(D)75K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001250853-21-000090) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML